[Individualization of polychemotherapy for stage III breast cancer based on immunologic status].
Immunologic response was studied in 91 cases of stage III breast cancer who received a CFMVP polychemotherapy. 23 patients were given decaris for immunostimulation. All cases showed a significant decrease in cellular immunity. CFMVP-treated patients showing a decrease of 30% and more should receive 300 mg of decaris twice a week for 3 weeks.
D000328:Adult; D000368:Aged; D000917:Antibody Formation / Q000187:drug effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy / Q000276:immunology*; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects; D007978:Levamisole / Q000627:therapeutic use; D008213:Lymphocyte Activation / Q000187:drug effects; D008727:Methotrexate / Q000008:administration & dosage / Q000009:adverse effects; D008875:Middle Aged; D011239:Prednisolone / Q000008:administration & dosage / Q000009:adverse effects; D011379:Prognosis; D014750:Vincristine / Q000008:administration & dosage / Q000009:adverse effects
D007978:Levamisole; D014750:Vincristine; D003520:Cyclophosphamide; D011239:Prednisolone; D005472:Fluorouracil; D008727:Methotrexate
Individualizatsiia polikhimioterapii pri rake molochnoĭ zhelezy III stadii v zavisimosti ot immunologicheskogo statusa.